Skip to main content

Scott Patterson, Bruce Johnson, Paul Waring

Transgenomic has established a clinical-commercial advisory board to help guide the development of its ICE COLD-PCR technology for oncology applications. The board is headed by Scott Patterson, vice president of biomarker sciences at Gilead Sciences. Also joining the board are Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute and Harvard Medical School professor, and Paul Waring, director of the Center for Translational Pathology at the University of Melbourne.

The Scan

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.